Vistagen Therapeutics, Inc. (VTGN) scores 28 out of 100 on boothcheck's 11-model valuation framework. Verdict: Bad The estimated fair value is $0.00. Quantitative score: 36/100. Qualitative score: 50/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.